| First Author | Kaneda H | Year | 2005 |
| Journal | Biochem Biophys Res Commun | Volume | 327 |
| Issue | 1 | Pages | 201-7 |
| PubMed ID | 15629449 | Mgi Jnum | J:95353 |
| Mgi Id | MGI:3525897 | Doi | 10.1016/j.bbrc.2004.12.004 |
| Citation | Kaneda H, et al. (2005) ICOS costimulates invariant NKT cell activation. Biochem Biophys Res Commun 327(1):201-7 |
| abstractText | It has been reported that costimulatory molecules, CD80/86-CD28 and CD154-CD40, critically contribute to activation of CD1d-restricted invariant NKT (iNKT) cells. Here we have demonstrated that ICOS, a new member of the CD28 family, plays a substantial role in iNKT cell activation. iNKT cells constitutively expressed ICOS as well as CD28 independently, and ICOS expression was further up-regulated 2-3 days after alpha-galactosylceramide (alpha-GalCer) treatment. Blockade of ICOS-mediated costimulation by administration of anti-ICOS ligand (B7RP-1) mAb or by ICOS gene knockout substantially inhibited alpha-GalCer-induced IFN-gamma and IL-4 production, cytotoxic activity, and anti-metastatic effect. Moreover, blockade of both B7RP-1-ICOS and CD80/86-CD28 interactions mostly abolished the alpha-GalCer-induced immune responses. These findings indicate that iNKT cell activation is regulated by CD28 and IOCS independently. |
